Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Key U.S. Senators Reach Deal on Funding Children’s Health Program

Reuters Staff  |  September 13, 2017

WASHINGTON (Reuters)—Leaders of the U.S. Senate Finance Committee said on Tuesday they reached an agreement to finance a federal insurance program for millions of lower-income children and pregnant women that was due to expire at the end of the month.

Republican Senator Orrin Hatch, chairman of the finance committee, and the panel’s top Democrat, Senator Ron Wyden, said in a statement the agreement would provide money for the Children’s Health Insurance Program (CHIP) for five years.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

CHIP reauthorization is not typically contentious as the program receives bipartisan support. But lobbyists and industry officials have said any healthcare-related legislation has become more complicated following the failure of Republicans to repeal and replace Obamacare.

“I am hopeful we can move forward swiftly to ensure no lapse in care for our nation’s most vulnerable children,” Hatch said in a statement, calling the agreement “a good first start.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Wyden said in a statement he hoped to get the extension of CHIP into law “as soon as possible.”

 

Share: 

Filed under:Legislation & Advocacy Tagged with:Children's Health Insurance Program (CHIP)lower-income childrenpregnant women

Related Articles

    Congressional Lawmakers Every Rheumatologist Should Know

    April 1, 2015

    Key leaders, committee members who can influence federal issues relevant to rheumatology

    Senate Finance Chairman Revises Tax Plan to End Obamacare Mandate

    November 15, 2017

    WASHINGTON (Reuters)—The head of the U.S. Senate Finance Committee proposed major changes to a Republican tax reform plan, adding a repeal of Obamacare’s health insurance mandate and making corporate tax cuts permanent while ending individual cuts in 2025. In a statement late on Tuesday, committee chairman Orrin Hatch said the proposed changes would also slightly…

    U.S. Senators Reach Bipartisan Deal on Obamacare Backed by Trump

    October 18, 2017

    WASHINGTON (Reuters)—On Tuesday, two U.S. senators announced a bipartisan breakthrough to shore up Obamacare for two years by reviving federal subsidies for health insurers that President Donald Trump planned to scrap, and the president voiced support for the plan. The agreement worked out by Sen. Lamar Alexander (R-Tenn.) and Sen. Patty Murray (D-Wash.) would meet…

    U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant

    February 28, 2019

    WASHINGTON/NEW YORK (Reuters)—U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines. Executives from Abbvie Inc., AstraZeneca PLC., Sanofi SA, Pfizer…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences